Clinical Trial Detail

NCT ID NCT02789657
Title Neoadjuvant Therapy in Clinical Stage I-III HER2-positive Breast Cancer.
Recruitment Active, not recruiting
Gender female
Phase Phase II
Variant Requirements Yes
Sponsors William Sikov MD
Indications

Her2-receptor positive breast cancer

Therapies

Carboplatin + Paclitaxel + Pertuzumab + Trastuzumab

Cyclophosphamide + Doxorubicin

Age Groups: senior adult

Additional content available in CKB BOOST